Order Article Reprints

Zerbit J, Detroit M, Meyer A, Decroocq J, Deau-Fischer B, Deschamps P, Birsen R, Mondesir J, Franchi P, Miekoutima E, et al. Patients with Hematological Malignancies Treated with T-Cell or B-Cell Immunotherapy Remain at High Risk of Severe Forms of COVID-19 in the Omicron Era. Viruses. 2022; 14(11):2377. https://doi.org/10.3390/v14112377

Zerbit, Jeremie, Marion Detroit, Antoine Meyer, Justine Decroocq, Benedicte Deau-Fischer, Paul Deschamps, Rudy Birsen, Johanna Mondesir, Patricia Franchi, Elsa Miekoutima, and et al. 2022. "Patients with Hematological Malignancies Treated with T-Cell or B-Cell Immunotherapy Remain at High Risk of Severe Forms of COVID-19 in the Omicron Era" Viruses 14, no. 11: 2377. https://doi.org/10.3390/v14112377

Zerbit, J., Detroit, M., Meyer, A., Decroocq, J., Deau-Fischer, B., Deschamps, P., Birsen, R., Mondesir, J., Franchi, P., Miekoutima, E., Guerin, C., Batista, R., Bouscary, D., Willems, L., & Vignon, M. (2022). Patients with Hematological Malignancies Treated with T-Cell or B-Cell Immunotherapy Remain at High Risk of Severe Forms of COVID-19 in the Omicron Era. Viruses, 14(11), 2377. https://doi.org/10.3390/v14112377